Ensign Peak Advisors’s Nektar Therapeutics NKTR Stock Holding History

Ensign Peak Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,581	Closed	-$220K	–	2074
2022 Q3	$220K	Hold	4,581	–	–	﹤0.01%	1844
2022 Q2	$261K	Hold	4,581	–	–	﹤0.01%	1716
2022 Q1	$370K	Hold	4,581	–	–	﹤0.01%	1676
2021 Q4	$928K	Sell	4,581 -5,386	-54%	-$1.17M	﹤0.01%	1333
2021 Q3	$2.69M	Hold	9,967	–	–	0.01%	946
2021 Q2	$2.56M	Hold	9,967	–	–	0.01%	978
2021 Q1	$2.99M	Hold	9,967	–	–	0.01%	863
2020 Q4	$2.54M	Hold	9,967	–	–	0.01%	931
2020 Q3	$2.48M	Hold	9,967	–	–	0.01%	851
2020 Q2	$3.46M	Hold	9,967	–	–	0.01%	720
2020 Q1	$2.67M	Hold	9,967	–	–	0.01%	712
2019 Q4	$3.23M	Buy	+9,967	New	+$2.89M	0.01%	813

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ensign Peak Advisors's NKTR Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Nektar Therapeutics (NKTR) in Q4 2022, closing a stake of 4,581 shares — an estimated $220K sold.

Ensign Peak Advisors first reported a position in NKTR in Q4 2019 and held it in 12 quarters. The position peaked at $3.46M in Q2 2020. 214 funds tracked by Wall St. Rank hold NKTR as of Q4 2022.

Ensign Peak Advisors reported no remaining Nektar Therapeutics position as of Q4 2022 after selling out during the quarter.
Ensign Peak Advisors sold 4,581 Nektar Therapeutics shares in Q4 2022, an estimated $220K.
Ensign Peak Advisors first reported a position in Nektar Therapeutics in Q4 2019 and held it in 12 quarters.
Ensign Peak Advisors's Nektar Therapeutics position peaked at $3.46M in Q2 2020.
214 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.